As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 16, 2012
by Genome Web
The New York Genome Center said today that it plans to sequence 1,000 genomes from Alzheimer’s patients over the next four years in order to better understand the genetic basis of the disease and the factors that contribute to disease risk and susceptibility.
The project is a collaboration between the NYGC, the Feinstein Institute for Medical Research, and Illumina, and will be the NYGC’s first large-scale sequencing project.
The nonprofit genome center, scheduled to open in the spring of 2012, is a consortium of 11 research institutes. The center will include both a CLIA-certified lab and an “Innovation Center” for emerging sequencing technologies. In the Alzheimer’s project, the researchers will begin by sequencing the whole genomes of 130 patient samples that have detailed clinical and brain pathology data, and then expand to 1,000 samples over the next four years.
The Alzheimer’s genomes will be compared to a control group of healthy elderly individuals and all the data will be made freely available. Peter Davies, the scientific director of the Litwin-Zucker Center for Research on Alzheimer’s Disease at the Feinstein Institute for Medical Research, will lead the effort.
The project is being funded through a grant by private philanthropists Frank and Mildred Feinberg and their family, in memory of Mildred Feinberg’s mother, who passed away from Alzheimer’s.
As part of the collaboration between the NYGC and Illumina, Illumina will provide early access to “key new products” and the NYGC will provide Illumina with access to its institutional founding members, which include Cold Spring Harbor Laboratory, Columbia University, Cornell University/Weill Cornell Medical College, the Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Mount Sinai Medical Center, New York-Presbyterian Hospital, New York University/NYU School of Medicine, North Shore-LIJ Health System, Rockefeller University, and Stony Brook University. The Hospital for Special Surgery is an associate founding member.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.